

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



**LANSEN PHARMACEUTICAL HOLDINGS LIMITED**

**朗生醫藥控股有限公司**

*(incorporated in the Cayman Islands with limited liability)*

**(Stock code: 503)**

**SUPPLEMENTAL ANNOUNCEMENT ON ESTIMATED PROFIT  
DECREASE FOR THE SIX MONTHS ENDED 30 JUNE 2021**

This announcement is made by Lansen Pharmaceutical Holdings Limited (the “**Company**”, together with its subsidiaries shall be referred to as the “**Group**”) pursuant to Rule 13.09(2)(a) of the Rules Governing the Listing of Securities on the Stock Exchange of Hong Kong Limited (the “**Listing Rules**”) and Part XI VA Insider Information Provisions (as defined in the Listing Rules) of the Securities and Futures Ordinance (Chapter 571, Laws of Hong Kong) (the “**SFO**”).

Reference is made to announcement of the Company dated 29 July 2021 on estimated profit decrease for the six months ended 30 June 2021 (the “**Announcement**”). Unless otherwise defined herein, capitalised terms used herein shall have the same meanings as those defined in the Announcement.

The Company wishes to further inform the shareholders of the Company and potential investors that based on the preliminary review of the unaudited consolidated management accounts of the Group for the six months ended 30 June 2021:

1. the Group’s revenue is expected to record a moderate decrease by approximately 14% as compared with that of the same period last year;
2. the Group’s operating profit is expected to record a significant decrease by approximately 49% as compared with that of the same period last year; and

3. the Group's net profit is expected to record a significant decrease by approximately 98% as compared with that of the same period last year. As mentioned in the Announcement, the decrease in the Group's net profit was due to the absence of a one-off net income arising from the reclassification of the interest in Starry as financial assets at fair value through profit or loss ("FVTPL") in the current period. Zhejiang Starry Pharmaceutical Company Limited ("Starry") is a company incorporated in the PRC and its shares are listed on Shanghai Stock Exchange. Starry was accounted for as an associate of the Company prior to the reclassification. As disclosed in the Group's 2020 Interim Report and 2020 Annual Report, as the shares held by the Group in Starry were less than 5%, the director appointed to Starry by the Group retired from the board of directors in 2020. According to applicable accounting standards, the Group had no right to exercise significant influence on Starry since then and therefore, Starry ceased to be an associate and the interest in Starry was reclassified as financial assets at FVTPL since 2020.

Save as disclosed above, all other information and content set out in the Announcement remain unchanged. This supplemental announcement is supplemental to and should be read in conjunction with the Announcement.

The information contained in this supplemental announcement and the Announcement is only a preliminary estimation by the management of the Group based on the unaudited consolidated management accounts of the Group for the six months ended 30 June 2021 and the information currently available, which have not been reviewed or audited by the auditors of the Company nor approved by the audit committee of the Company. Therefore, the actual results of the Group for the six months ended 30 June 2021 may be different from the information contained herein.

**Shareholders of the Company and potential investors should exercise caution when dealing in the securities of the Company.**

By order of the Board  
**Lansen Pharmaceutical Holdings Limited**  
**Wu Zhen Tao**  
*Chairman*

Hong Kong, 3 August 2021

*As at the date of this announcement, the executive managing Director is Mr. Chen Li; the non-executive Directors are Mr. Wu Zhen Tao, Mr. Stephen Burnau Hunt and Ms. Liu Xuezi; the independent non-executive Directors are Mr. Chan Kee Huen, Michael, Mr. Fritz Heinrich Horlacher and Mr. Yeung Tak Bun, Allen.*